autologous tumor infiltrating lymphocyte
/ CAR-T (Shanghai) Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 04, 2020
A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
(clinicaltrials.gov)
- P1/2; N=40; Active, not recruiting; Sponsor: CAR-T (Shanghai) Cell Biotechnology Co., Ltd.
Clinical • New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1